文献速递血栓与止血

疫苗诱导免疫性血栓性血小板减少症中大多数抗PF4抗体为一过性

Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.
PubMed 文献 · Blood · 2022-01-01

这项观察性研究随访65例疫苗诱导免疫性血栓性血小板减少症(VITT)患者,中位随访25周。48/65例(73.8%;CI 62.0%至83.0%)患者功能性检测转阴,中位转阴时间15.5周(范围5-28周)。29例接种第二剂mRNA新冠疫苗的患者均未出现新发血栓或抗PF4/肝素IgG EIA OD值相关升高。

要点

  • VITT患者中大多数PF4依赖性血小板活化抗体为一过性,中位15.5周转阴。
  • 48/65例(73.8%;CI 62.0%至83.0%)患者功能性检测转阴。
  • 29例接种第二剂mRNA新冠疫苗的VITT患者未出现新发血栓或抗PF4/肝素IgG EIA OD值相关升高。

核心结论

  • PF4依赖性血小板活化抗体在大多数VITT患者中为一过性。
  • VITT患者可安全接种第二剂新冠mRNA疫苗。

研究设计与样本

  • 观察性研究,随访65例VITT患者(41例女性;中位年龄51岁,范围18-80岁)。
  • 中位随访25周(范围3-36周)。
  • 通过抗PF4/肝素IgG酶免疫测定(EIA)和PF4依赖性血小板活化抗体功能检测评估抗体反应性变化,并记录新发血栓并发症。

主要发现

  • 48/65例患者(73.8%;CI 62.0%至83.0%)功能性检测转阴,中位转阴时间15.5周(范围5-28周)。
  • EIA光密度(OD)值从基线中位3.12降至1.52(P < .0001),但仅14例(21.5%)患者出现血清学转阴。
  • 5例(7.5%)患者持续存在血小板活化抗体和高EIA OD值超过11周。
  • 29例接种第二剂mRNA新冠疫苗的VITT患者中,无论PF4依赖性血小板活化抗体是否仍存在,均未出现新发血栓或抗PF4/肝素IgG EIA OD值相关升高。

临床怎么用

  • 作者指出,VITT患者可安全接种第二剂新冠mRNA疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine-induced thrombotic thrombocytopenia (VITT) is triggered by vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2-S). In this observational study, we followed VITT patients for changes in their reactivity of platelet-activating antiplatelet factor 4 (PF4) immunoglobulin G (IgG) antibodies by an anti-PF4/heparin IgG enzyme immunoassay (EIA) and a functional test for PF4-dependent, platelet-activating antibodies, and new thrombotic complications. Sixty-five VITT patients (41 females; median, 51 years; range, 18-80 years) were followed for a median of 25 weeks (range, 3-36 weeks). In 48/65 patients (73.8%; CI, 62.0% to 83.0%) the functional assay became negative. The median time to negative functional test result was 15.5 weeks (range, 5-28 weeks). In parallel, EIA optical density (OD) values decreased from median 3.12 to 1.52 (P < .0001), but seroreversion to a negative result was seen in only 14 (21.5%) patients. Five (7.5%) patients showed persistent platelet-activating antibodies and high EIA ODs for >11 weeks. None of the 29 VITT patients who received a second vaccination dose with an mRNA COVID-19 vaccine developed new thromboses or relevant increase in anti-PF4/heparin IgG EIA OD, regardless of whether PF4-dependent platelet-activating antibodies were still present. PF4-dependent platelet-activating antibodies are transient in most patients with VITT. VITT patients can safely receive a second COVID-19 mRNA-vaccine shot.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schönborn L, Thiele T, Kaderali L, et al. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood. 2022. PMID: 35113987. doi:10.1182/blood.2021014214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。